OS Therapies (NYSEAMERICAN:OSTX) Cut to “Strong Sell” at Zacks Research

Zacks Research lowered shares of OS Therapies (NYSEAMERICAN:OSTX) from a hold rating to a strong sell rating in a research note issued to investors on Monday,Zacks.com reports.

Separately, D. Boral Capital reaffirmed a “buy” rating and issued a $20.00 price objective on shares of OS Therapies in a research note on Friday, October 10th. Three investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $18.00.

OS Therapies Price Performance

NYSEAMERICAN OSTX opened at $1.95 on Monday. The stock’s 50-day simple moving average is $2.12 and its two-hundred day simple moving average is $1.84. OS Therapies has a twelve month low of $1.12 and a twelve month high of $7.00. The company has a market capitalization of $61.72 million, a price-to-earnings ratio of -2.47 and a beta of -4.09.

Hedge Funds Weigh In On OS Therapies

Hedge funds have recently modified their holdings of the company. CM Management LLC grew its stake in shares of OS Therapies by 172.6% in the first quarter. CM Management LLC now owns 300,000 shares of the company’s stock worth $462,000 after purchasing an additional 189,956 shares during the last quarter. XTX Topco Ltd purchased a new stake in OS Therapies in the 2nd quarter worth approximately $63,000. Finally, Bridgeway Capital Management LLC bought a new stake in shares of OS Therapies in the 2nd quarter worth approximately $47,000.

About OS Therapies

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers.